{"brief_title": "Study of T900607-Sodium in Previously Treated Patients With Ovarian Cancer.", "brief_summary": "The purpose of this study is to determine whether T900607-sodium is effective and safe in treating ovarian cancer.", "condition": ["Ovarian Neoplasms"], "intervention_type": ["Drug"], "intervention_name": ["intravenous T900607-sodium"], "criteria": "Inclusion Criteria - Histologically or cytologically confirmed diagnosis of ovarian cancer - Subjects must have received 1-2 regimens of prior chemotherapy (with one containing paclitaxel) - At least 18 years of age - Bidimensionally measurable disease amenable to CT scanning. At least one lesion must be least 1 X 1 cm in size. - Karnofsky performance status of at least 70% - Estimated life expectancy of at least 12 weeks - Females of childbearing potential must have a negative pregnancy test and agree to use an effective contraceptive - Subject must be able to comply with study procedures and follow-up examinations. - Signed written informed consent - Lab Values (obtained \u2264 7 days prior to study enrollment): - ANC at least 1.5x10e9/L, - Platelet count at least 100x10e9/L, - Hemoglobin at least 8.5 g/dL, - Creatinine within 2 times upper limit of normal - AST and ALT within 3 times upper limit of normal - Bilirubin within 1.5 times upper limit of normal - Albumin great than 2.5 g/dL - INR < 1.5 for subjects without anticoagulants Exclusion Criteria - Severe, concurrent disease, infection or co-morbidity that, in the judgment of the investigator, would make the subject inappropriate for enrollment - NYHA Class III/IV cardiac disease, left ventricular ejection fraction (LVEF) of <50%, or acute anginal symptoms - Patients who have received any investigational agent within 4 weeks of enrollment - Patients who are pregnant or breast-feeding - History of prior malignancy other than ovarian cancer within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix - History of central nervous system metastases or carcinomatous meningitis - Major surgery within 4 weeks of enrollment", "gender": "Female", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Ovarian Neoplasms"], "id": "NCT00043446"}